JUNSHI BIO (01877) saw its shares rise more than 3% after the release of its financial results. At the time of writing, the stock was up 3.3%, trading at HK$26.94, with a turnover of HK$9.23 million. On April 27, the company announced that for the first quarter of 2026, its revenue reached approximately RMB 726 million, representing a year-on-year increase of 45.09%. The net loss attributable to shareholders was about RMB 20.564 million, narrowing by 91.24% compared to the same period last year. The basic loss per share was RMB 0.02. The growth in revenue during the reporting period was primarily driven by increased sales from commercialized drugs. Among these, the core product, toripalimab injection (brand name: Tuoyi®/LOQTORZI®, product code: JS001), generated domestic sales revenue of approximately RMB 623 million, up about 39.37% year-on-year. The company stated that the reduction in losses was mainly due to higher sales from commercialized drugs compared to the same period last year, as well as efforts to enhance R&D and sales efficiency under its "quality improvement and efficiency enhancement" initiative.